![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/NECLIFE.png)
Share the post "Nectar Lifesciences ‘s Q3 2024-25 Latest News: Profit Rises by 399.36% YoY"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 0.62 % in the past year, substantial increase in net sales/revenue by 6.28 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 19.38 %. Marginal decrease of -16.84% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Nectar Lifesciences Limited. Notable increase of 400.32 % in net profit Year to Year, Nectar Lifesciences Limited’s profitability increased by 40.03 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 400.00 % Year to Year. EPS increased by 40 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 452.171 Cr | Rs. 428.098 Cr | Rs. 454.982 Cr | + 6.28 % | + 0.62 % |
| Expenses | Rs. 409.98 Cr | Rs. 384.76 Cr | Rs. 410.27 Cr | + 6.63 % | + 0.07 % |
| Operating Profit | Rs. 42.19 Cr | Rs. 43.34 Cr | Rs. 44.71 Cr | + 3.16 % | + 5.97 % |
| OPM % | 9.33 % | 10.12 % | 9.83 % | -0.29 % | + 0.5 % |
| Other Income | Rs. 0.48 Cr | Rs. 0.689 Cr | Rs. 0.573 Cr | -16.84 % | + 19.38 % |
| Interest | Rs. 24.84 Cr | Rs. 19.81 Cr | Rs. 17.12 Cr | -13.58 % | -31.08 % |
| Depreciation | Rs. 15.37 Cr | Rs. 15.55 Cr | Rs. 15.61 Cr | + 0.39 % | + 1.56 % |
| Profit before tax | Rs. 2.46 Cr | Rs. 8.67 Cr | Rs. 12.55 Cr | + 44.75 % | + 410.16 % |
| Tax % | 36.22 % | 35.39 % | 37.51 % | + 2.12 % | + 1.29 % |
| Net Profit | Rs. 1.57 Cr | Rs. 5.6 Cr | Rs. 7.84 Cr | + 40 % | + 399.36 % |
| EPS in Rs | Rs. 0.07 | Rs. 0.25 | Rs. 0.35 | + 40 % | + 400 % |
Today, we’re looking at Nectar Lifesciences Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 0.62 %. However, it did see a marginal increase of 6.28 % from the previous quarter. Expenses ticked up slightly by 6.63 % quarter-on-quarter, aligning with the annual rise of 0.07 %. Operating profit, while up 5.97 % compared to last year, faced a quarter-on-quarter increase of 3.16 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 0.5 %, but a shrinkage of -0.29 % sequentially. Other income fell by -16.84 % compared to the last quarter, despite an annual growth of 19.38 %. Interest expenses dropped significantly by -13.58 % from the previous quarter, yet the year-over-year decrease remains at a moderate -31.08 %. Depreciation costs climbed by 0.39 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 1.56 %. Profit before tax grew annually by 410.16 % but saw an increase from the preceding quarter by 44.75 %.
Tax expenses as a percentage of profits increased slightly by 1.29 % compared to last year, with a more notable quarter-on-quarter increase of 2.12 %. Net profit rose by 399.36 % year-on-year but experienced a 40 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 400 % but a quarterly rise of 40 %. In summary, Nectar Lifesciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 452.171 Cr | Rs. 428.098 Cr | Rs. 454.982 Cr | + 6.28 % | + 0.62 % |
| Expenses | Rs. 409.98 Cr | Rs. 384.76 Cr | Rs. 410.27 Cr | + 6.63 % | + 0.07 % |
| Operating Profit | Rs. 42.19 Cr | Rs. 43.34 Cr | Rs. 44.71 Cr | + 3.16 % | + 5.97 % |
| Net Profit | Rs. 1.57 Cr | Rs. 5.6 Cr | Rs. 7.84 Cr | + 40 % | + 399.36 % |
| EPS in Rs | Rs. 0.07 | Rs. 0.25 | Rs. 0.35 | + 40 % | + 400 % |
In reviewing Nectar Lifesciences Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 0.62 % year-on-year growth, however, there was a minor increase of 6.28 % from the previous quarter. Expenses rose by 0.07 % compared to the previous year, with a 6.63 % increase quarter-on-quarter. Operating Profit surged by 5.97 % annually, and saw a 3.16 % increase from the last quarter.
Net Profit showed yearly increase of 399.36 %, and experienced a 40 % increase from the previous quarter. Earnings Per Share (EPS) rose by 400 % annually, however rose by 40 % compared to the last quarter. In essence, while Nectar Lifesciences Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/MANGCHEFER.png)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/GUJGASLTD.png)